TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC reduced its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 53.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 87,133 shares of the company's stock after selling 98,195 shares during the period. Nuveen Asset Management LLC owned 0.26% of TransMedics Group worth $5,433,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in TMDX. Janney Montgomery Scott LLC purchased a new position in TransMedics Group in the fourth quarter worth approximately $239,000. Perigon Wealth Management LLC grew its holdings in shares of TransMedics Group by 212.4% during the 4th quarter. Perigon Wealth Management LLC now owns 14,277 shares of the company's stock worth $828,000 after purchasing an additional 9,707 shares during the period. Clear Creek Financial Management LLC purchased a new position in shares of TransMedics Group during the 4th quarter worth $352,000. Abundance Wealth Counselors increased its position in shares of TransMedics Group by 10.6% during the 4th quarter. Abundance Wealth Counselors now owns 5,529 shares of the company's stock worth $345,000 after purchasing an additional 528 shares during the last quarter. Finally, CENTRAL TRUST Co raised its holdings in TransMedics Group by 162.2% in the 4th quarter. CENTRAL TRUST Co now owns 1,442 shares of the company's stock valued at $90,000 after buying an additional 892 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.

TransMedics Group Stock Performance

TransMedics Group stock traded up $6.71 during midday trading on Tuesday, hitting $130.65. 562,094 shares of the company's stock were exchanged, compared to its average volume of 1,354,964. The firm's 50 day simple moving average is $96.37 and its 200 day simple moving average is $78.80. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The stock has a market cap of $4.42 billion, a price-to-earnings ratio of 138.99 and a beta of 1.91. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.41. The company had revenue of $143.54 million for the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company's revenue was up 48.2% on a year-over-year basis. During the same period last year, the business posted $0.35 EPS. Equities research analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Activity

In related news, Director David Weill sold 732 shares of TransMedics Group stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total transaction of $90,680.16. Following the completion of the transaction, the director now directly owns 12,134 shares of the company's stock, valued at approximately $1,503,159.92. The trade was a 5.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Edward M. Basile sold 6,000 shares of the business's stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $115.63, for a total transaction of $693,780.00. Following the completion of the sale, the director now owns 732 shares in the company, valued at $84,641.16. This represents a 89.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,732 shares of company stock valued at $1,416,710 over the last quarter. Corporate insiders own 7.00% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Oppenheimer upped their price objective on shares of TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Piper Sandler reiterated an "overweight" rating and issued a $125.00 price objective (up previously from $105.00) on shares of TransMedics Group in a research note on Friday, May 9th. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a report on Tuesday. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $104.00 price objective on shares of TransMedics Group in a report on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, TransMedics Group has a consensus rating of "Moderate Buy" and a consensus target price of $126.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.